Disrupted steroid synthesis in PCOS: mechanisms and treatment evidence examined in a review
Background
A review examines how dysregulation of ovarian steroid hormone synthesis in polycystic ovary syndrome (PCOS) relates to reproductive and metabolic problems. The authors survey abnormalities in relevant enzymes and signaling, distinguishing established treatments from approaches still under study or at the conceptual stage. The paper synthesizes existing knowledge; it does not report treatment effects in a new patient cohort.
PCOS is the most common endocrine and metabolic disorder among women of reproductive age. Its main features include elevated blood androgen levels, anovulation, and polycystic ovarian morphology. The review examines existing knowledge from the perspective that abnormalities in ovarian hormone synthesis act alongside neuroendocrine and metabolic dysfunction. Its scope extends beyond imbalances in circulating hormones to the enzymes that produce hormones and the signals that regulate them.
Key findings
The review focuses on dysregulation of steroid-synthesis enzymes and related signaling pathways. The authors explain that these abnormalities contribute to androgen excess and estrogen deficiency and are also linked to impaired follicular development and metabolic dysfunction. They present these abnormalities as molecular connections that help explain ovarian reproductive function and metabolic problems together.
Communication between theca and granulosa cells is also examined. The paper discusses how molecular dysregulation disrupts interactions between the two cell types, impedes follicular development, and contributes to ovarian androgen excess, oxidative stress, and insulin resistance. However, the available abstract does not provide detailed experimental results for individual enzymes or signaling pathways.
The review also emphasizes differences among patients. Changes in steroid synthesis do not occur in the same way in all patients with PCOS; they vary with clinical phenotype, including the presence or absence of androgen excess, ovulatory status, lean versus obese body type, and reproductive and metabolic characteristics. This suggests that molecular abnormalities are difficult to interpret uniformly even among patients with the same diagnosis. The abstract describes this heterogeneity but does not report the magnitude of phenotype-specific differences or their ability to predict treatment response.
Treatment strategies are grouped by level of evidence. Lifestyle interventions, insulin sensitizers, ovulation-induction agents, hormonal regulators, and antiandrogens are presented as established treatment categories. Inhibitors targeting specific enzymes are approaches under study. Gene editing and exosome-based delivery systems are discussed as speculative precision-treatment concepts supported by more limited evidence. This distinction provides a basis for separating mechanistic possibilities from clinically demonstrated treatments.
Implications and outlook
By considering abnormalities in ovarian enzyme regulation alongside patient heterogeneity, the review points to directions for treatment research targeting biochemical abnormalities. The authors identify research into the interdependence of enzymes and signaling, and the development of personalized treatments tailored to biochemical abnormalities in PCOS, as priorities for future work.
Understanding enzyme regulation could help guide the design of interventions intended to improve reproductive function and reduce long-term metabolic risk. These are research aims, however, not clinical outcomes established by the review. The available material consists of bibliographic information and an abstract, so participant numbers, comparison conditions, effect sizes, and follow-up periods in individual studies could not be verified. Additional evidence is needed to assess the clinical efficacy and safety of enzyme-targeted treatments, gene editing, and exosome delivery. The review’s scope and the levels of treatment evidence can be checked in the paper abstract.
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine-metabolic disorder in women of reproductive age, and is characterized by hyperandrogenism, anovulation, and polycystic ovarian morphology. Emerging molecular evidence has identified dysregulated ovarian steroidogenesis as a major contributing mechanism linking reproductive and metabolic phenotypes in PCOS, acting in concert with neuroendocrine and metabolic dysfunction. This review synthesizes current knowledge on enzymatic and regulatory perturbations driving androgen excess and estrogen deficiency in PCOS, emphasizing their mechanistic, diagnostic, and therapeutic implications. Dysregulated steroidogenic enzymes and associated signaling pathways contribute to androgen excess, impaired folliculogenesis, and metabolic dysfunction in PCOS. Importantly, these steroidogenic alterations are not uniform across all patients with PCOS but vary according to hyperandrogenic, anovulatory, ovulatory, lean, obese, reproductive, and metabolic phenotypes. Particular focus is placed on how these molecular derangements disrupt theca-granulosa cell communication, impair folliculogenesis, and promote hyperandrogenism, oxidative stress, and insulin resistance in the ovaries. This review also discusses therapeutic strategies according to evidence level, distinguishing established PCOS treatments such as lifestyle intervention, insulin sensitizers, ovulation-induction agents, hormonal regulators, and anti-androgens from investigational enzyme-specific inhibitors and speculative precision approaches such as gene editing and exosome-based delivery systems. Collectively, these insights underscore that the pathophysiology of PCOS extends beyond endocrine imbalance to encompass multi-omic alterations in metabolism and signaling. Understanding enzyme-level dysregulation offers opportunities for mechanism-based interventions that can restore steroidogenic homeostasis, improve fertility outcomes, and mitigate long-term metabolic r
Consider a patient with PCOS who encounters information about enzyme inhibitors or exosome treatments and asks during a consultation whether they could be used in care. This review can help explain the distinction between established treatments, such as lifestyle interventions and medication, enzyme inhibitors still under study, and speculative approaches involving gene editing or exosomes. It is not a guideline for determining an individual patient’s treatment.
For research and development, the review points toward analyzing enzyme and signaling abnormalities while accounting for differences among patients. For example, it could serve as a starting point for follow-up studies testing relationships among clinical phenotype, biochemical abnormalities, and treatment response. It does not provide evidence for assigning a particular targeted treatment based solely on weight or ovulatory status, or for guaranteeing restored fertility or fewer adverse effects.